Skip to content
Search AI Powered

Latest Stories

Alliance Pharma founder donates £5m to create University of Sunderland's new drug research centre

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre.

The donation – the biggest in the university’s history – will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide.


The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding.

He and Sam were on Thursday (April 20) joined by specially invited guests from across the region’s health, education, and business communities, to launch the Institute housed in the University’s Sciences Complex.

2023pr047pic4 John Dawson and his wife Sam outside the John Dawson Drug Discovery and Development Research Institute at the University of Sunderland’s City Campus. Picture: DAVID WOOD

Unveiling a plaque inside the building, John said: “It’s an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today.

“It’s been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago.

“I was immediately impressed at what has been achieved in that intervening half-century and I’ve been delighted to assist the University continue its development, particularly in the health arena.

“I hope the launch of this institute will mark the next phase in the University’s evolution and I’m very much looking forward to working with the team as they bring their projects to fruition.”

The new institute will play a key role in turning laboratory research and innovation into life-changing therapies for clinical practice, working closely with the NHS and the pharmaceutical industry.

It will also bring together expertise in clinical, laboratory and data science to address issues of local, national and international importance and focus on on areas including the discovery of new medicines for the treatment of rare inherited metabolic diseases -- developing targeted delivery methods and technologies to improve pharmaceutical manufacturing processes as well as the development and application of machine learning tools for early disease detection.

2023pr047pic3 John Dawson and his wife Sam pictured with the university's vice chancellor and chief executive Sir David Bell (L). Picture: DAVID WOOD

Sir David Bell, Newcastle University’s vice-chancellor and chief executive, said: “I am enormously grateful to John and Sam Dawson for their immense generosity in supporting this new Research Institute in the crucially important fields of drug discovery and development.

"The fact that John is ‘one of us’ is an added bonus as his life and career demonstrate the good that our graduates do in so many different walks of life.”

After graduating from Sunderland Polytechnic in 1970, Newcastle-born John went on to build a successful career in the pharmaceutical industry. He founded the prescription medicines and consumer healthcare company, Alliance Pharma, in 1996.

Commenced trading in 1998 with just two full-time employees in the UK, the company expanded over the next 20 years. John turned it into an international pharmaceutical powerhouse with sales now exceeding £170m, operating out of nine offices in eight countries with more than 280 employees.

He stepped down from Alliance Pharma in 2019.

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less